Business Context and Reporting Period
This Form 8-K was filed by Sonoma Pharmaceuticals, Inc. (formerly Oculus Innovative Sciences, Inc.) on December 6, 2016. The report documents a corporate name change effective as of the filing date.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report is a current report regarding corporate governance changes and does not contain financial statements or performance metrics.
Material Changes
- Corporate Name Change: Effective December 6, 2016, the company changed its name from Oculus Innovative Sciences, Inc. to Sonoma Pharmaceuticals, Inc.
- Legal Amendments: The change was executed pursuant to Section 242 of the Delaware General Corporation Law by amending Article I of the Restated Certificate of Incorporation.
- Bylaws Update: The company amended its bylaws to substitute the new name for the former name in the title.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the announcement of the name change and the filing of related exhibits.
Key Facts for Investor Verification
- Verify the effective date of the name change (December 6, 2016).
- Confirm the filing of the Certificate of Amendment with the Delaware Secretary of State.
- Review the attached exhibits (3.1 and 3.2) for the full text of the amended Certificate of Incorporation and Bylaws.
- Note that this filing does not impact the company's financial position or operational results.